drugset / Trial / NCT00505778

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778

Phase 3 Completed 1027 enrolled Warner Chilcott
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.

Timeline

Start
2007-07
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mesalamine Small molecule 1.6 g Oral
Comparator Mesalamine Small molecule 2.4 g Oral

Indications